M.K. Keng, M.A. Sekeres. Febrile neutropenia in hematologic malignancies. „Curr Hematol Malig Rep”. 8 (4), s. 370–378, Dec 2013. DOI: 10.1007/s11899-013-0171-4. PMID: 23990311.
S. Alp, M. Akova. Management of febrile neutropenia in the era of bacterial resistance. „Ther Adv Infect Dis”. 1 (1), s. 37–43, Feb 2013. DOI: 10.1177/2049936113475610. PMID: 25165543.
F. Koinis, G. Nintos, V. Georgoulias, A. Kotsakis. Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors. „Expert Opin Pharmacother”. 16 (10), s. 1505–1519, 2015. DOI: 10.1517/14656566.2015.1055248. PMID: 26077189.
A.G. Freifeld, E.J. Bow, K.A. Sepkowitz, M.J. Boeckh i inni. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. „Clin Infect Dis”. 52 (4), s. e56-93, Feb 2011. DOI: 10.1093/cid/cir073. PMID: 21258094.
M.A. Lewis, A.W. Hendrickson, T.J. Moynihan. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. „CA Cancer J Clin”. 61 (5). s. 287–314. DOI: 10.3322/caac.20124. PMID: 21858793.
O. Yapici, F. Gunseren, H. Yapici, A. Merdin i inni. Evaluation of febrile neutropenic episodes in adult patients with solid tumors. „Mol Clin Oncol”. 4 (3), s. 379–382, Mar 2016. DOI: 10.3892/mco.2015.722. PMID: 26998287.
E. Garbe. Non-chemotherapy drug-induced agranulocytosis. „Expert Opin Drug Saf”. 6 (3), s. 323–335, May 2007. DOI: 10.1517/14740338.6.3.323. PMID: 17480181.
N.M. Kuderer, D.C. Dale, J. Crawford, L.E. Cosler i inni. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. „Cancer”. 106 (10), s. 2258–2266, May 2006. DOI: 10.1002/cncr.21847. PMID: 16575919.
S. Schelenz, D. Giles, S. Abdallah. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. „Ann Oncol”. 23 (7), s. 1889–1893, Jul 2012. DOI: 10.1093/annonc/mdr520. PMID: 22048152.
G.H. Lyman, E. Abella, R. Pettengell. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. „Crit Rev Oncol Hematol”. 90 (3), s. 190–199, Jun 2014. DOI: 10.1016/j.critrevonc.2013.12.006. PMID: 24434034.
R. Pettengell, A. Bosly, T.D. Szucs, C. Jackisch i inni. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. „Br J Haematol”. 144 (5), s. 677–685, Mar 2009. DOI: 10.1111/j.1365-2141.2008.07514.x. PMID: 19055662.
R.A. Laskey, M.S. Poniewierski, M.A. Lopez, R.K. Hanna i inni. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. „Gynecol Oncol”. 125 (3), s. 625–630, Jun 2012. DOI: 10.1016/j.ygyno.2012.03.015. PMID: 22426251.
A. Salar, C. Haioun, F.G. Rossi, U. Duehrsen i inni. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. „Leuk Res”. 36 (5), s. 548–553, May 2012. DOI: 10.1016/j.leukres.2012.02.002. PMID: 22385870.
K. Ozawa, H. Minami, H. Sato. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. „Cancer Chemother Pharmacol”. 62 (3), s. 551–557, Aug 2008. DOI: 10.1007/s00280-007-0648-8. PMID: 18064462.
W. Hosmer, J. Malin, M. Wong. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. „Support Care Cancer”. 19 (3), s. 333–341, Mar 2011. DOI: 10.1007/s00520-010-0821-1. PMID: 20179995.
J. Gea-Banacloche. Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies. „Hematology Am Soc Hematol Educ Program”. 2013, s. 414–422, 2013. DOI: 10.1182/asheducation-2013.1.414. PMID: 24319213.
N. Pherwani, J.M. Ghayad, L.M. Holle, E.L. Karpiuk. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review. „Am J Health Syst Pharm”. 72 (8), s. 619–631, Apr 2015. DOI: 10.2146/ajhp140194. PMID: 25825185.
A. Uys, B.L. Rapoport, R. Anderson. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. „Support Care Cancer”. 12 (8), s. 555–560, Aug 2004. DOI: 10.1007/s00520-004-0614-5. PMID: 15197637.
L. de Souza Viana, J.C. Serufo, M.O. da Costa Rocha, R.N. Costa i inni. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. „Support Care Cancer”. 16 (7), s. 841–846, Jul 2008. DOI: 10.1007/s00520-007-0347-3. PMID: 17960431.
E.P. Hui, L.K. Leung, T.C. Poon, F. Mo i inni. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. „Support Care Cancer”. 19 (10), s. 1625–1635, Oct 2011. DOI: 10.1007/s00520-010-0993-8. PMID: 20820815.
H. Innes, S.L. Lim, A. Hall, S.Y. Chan i inni. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. „Support Care Cancer”. 16 (5), s. 485–491, May 2008. DOI: 10.1007/s00520-007-0334-8. PMID: 17899215.
C. Fontanella, S. Bolzonello, B. Lederer, G. Aprile. Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. „Breast Care (Basel)”. 9 (4), s. 239–245, Apr 2014. DOI: 10.1159/000366466. PMID: 25404882.
K.C. Lakshmaiah, A.S. Malabagi, R. Govindbabu, M. Shetty i inni. Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients. „J Lab Physicians”. 7 (2). s. 116–120. DOI: 10.4103/0974-2727.163126. PMID: 26417163.
P. Villafuerte-Gutierrez, L. Villalon, J.E. Losa, C. Henriquez-Camacho. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. „Adv Hematol”. 2014, s. 986938, 2014. DOI: 10.1155/2014/986938. PMID: 25525436.
M. Paul, D. Yahav, A. Bivas, A. Fraser i inni. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. „Cochrane Database Syst Rev”, s. CD005197, 2010. DOI: 10.1002/14651858.CD005197.pub3. PMID: 21069685.
M. Paul, Y. Dickstein, A. Schlesinger, S. Grozinsky-Glasberg i inni. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. „Cochrane Database Syst Rev”, s. CD003038, 2013. DOI: 10.1002/14651858.CD003038.pub2. PMID: 23813455.
O.A. Clark, G.H. Lyman, A.A. Castro, L.G. Clark i inni. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. „J Clin Oncol”. 23 (18), s. 4198–4214, Jun 2005. DOI: 10.1200/JCO.2005.05.645. PMID: 15961767.
L. Vidal, M. Paul, I. Ben dor, K. Soares-Weiser i inni. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. „J Antimicrob Chemother”. 54 (1), s. 29–37, Jul 2004. DOI: 10.1093/jac/dkh303. PMID: 15201227.
L. Vidal, I. Ben Dor, M. Paul, N. Eliakim-Raz i inni. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. „Cochrane Database Syst Rev”, s. CD003992, 2013. DOI: 10.1002/14651858.CD003992.pub3. PMID: 24105485.
O. Teuffel, M.C. Ethier, S.M. Alibhai, J. Beyene i inni. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. „Ann Oncol”. 22 (11), s. 2358–2365, Nov 2011. DOI: 10.1093/annonc/mdq745. PMID: 21363878.
S. Cetean, C. Căinap, A.M. Constantin, S. Căinap i inni. The importance of the granulocyte-colony stimulating factor in oncology. „Clujul Med”. 88 (4), s. 468–472, 2015. DOI: 10.15386/cjmed-531. PMID: 26732055.
C.L. Vogel, M.Z. Wojtukiewicz, R.R. Carroll, S.A. Tjulandin i inni. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. „J Clin Oncol”. 23 (6), s. 1178–1184, Feb 2005. DOI: 10.1200/JCO.2005.09.102. PMID: 15718314.
J.N. Timmer-Bonte, T.M. de Boo, H.J. Smit, B. Biesma i inni. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. „J Clin Oncol”. 23 (31), s. 7974–7984, Nov 2005. DOI: 10.1200/JCO.2004.00.7955. PMID: 16258098.
G.H. Lyman, D.C. Dale, E. Culakova, M.S. Poniewierski i inni. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. „Ann Oncol”. 24 (10), s. 2475–2484, Oct 2013. DOI: 10.1093/annonc/mdt226. PMID: 23788754.
P. Renner, S. Milazzo, J.P. Liu, M. Zwahlen i inni. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. „Cochrane Database Syst Rev”. 10, s. CD007913, 2012. DOI: 10.1002/14651858.CD007913.pub2. PMID: 23076939.
M.K. Keng, M.A. Sekeres. Febrile neutropenia in hematologic malignancies. „Curr Hematol Malig Rep”. 8 (4), s. 370–378, Dec 2013. DOI: 10.1007/s11899-013-0171-4. PMID: 23990311.
M.S. Cairo. Dose reductions and delays: limitations of myelosuppressive chemotherapy. „Oncology (Williston Park)”. 14 (9 Suppl 8), s. 21–31, Sep 2000. PMID: 11033835.
S. Alp, M. Akova. Management of febrile neutropenia in the era of bacterial resistance. „Ther Adv Infect Dis”. 1 (1), s. 37–43, Feb 2013. DOI: 10.1177/2049936113475610. PMID: 25165543.
F. Koinis, G. Nintos, V. Georgoulias, A. Kotsakis. Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors. „Expert Opin Pharmacother”. 16 (10), s. 1505–1519, 2015. DOI: 10.1517/14656566.2015.1055248. PMID: 26077189.
A.G. Freifeld, E.J. Bow, K.A. Sepkowitz, M.J. Boeckh i inni. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. „Clin Infect Dis”. 52 (4), s. e56-93, Feb 2011. DOI: 10.1093/cid/cir073. PMID: 21258094.
M.A. Lewis, A.W. Hendrickson, T.J. Moynihan. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. „CA Cancer J Clin”. 61 (5). s. 287–314. DOI: 10.3322/caac.20124. PMID: 21858793.
O. Yapici, F. Gunseren, H. Yapici, A. Merdin i inni. Evaluation of febrile neutropenic episodes in adult patients with solid tumors. „Mol Clin Oncol”. 4 (3), s. 379–382, Mar 2016. DOI: 10.3892/mco.2015.722. PMID: 26998287.
E. Garbe. Non-chemotherapy drug-induced agranulocytosis. „Expert Opin Drug Saf”. 6 (3), s. 323–335, May 2007. DOI: 10.1517/14740338.6.3.323. PMID: 17480181.
N.M. Kuderer, D.C. Dale, J. Crawford, L.E. Cosler i inni. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. „Cancer”. 106 (10), s. 2258–2266, May 2006. DOI: 10.1002/cncr.21847. PMID: 16575919.
S. Schelenz, D. Giles, S. Abdallah. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. „Ann Oncol”. 23 (7), s. 1889–1893, Jul 2012. DOI: 10.1093/annonc/mdr520. PMID: 22048152.
G.H. Lyman, E. Abella, R. Pettengell. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. „Crit Rev Oncol Hematol”. 90 (3), s. 190–199, Jun 2014. DOI: 10.1016/j.critrevonc.2013.12.006. PMID: 24434034.
R. Pettengell, A. Bosly, T.D. Szucs, C. Jackisch i inni. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. „Br J Haematol”. 144 (5), s. 677–685, Mar 2009. DOI: 10.1111/j.1365-2141.2008.07514.x. PMID: 19055662.
R.A. Laskey, M.S. Poniewierski, M.A. Lopez, R.K. Hanna i inni. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. „Gynecol Oncol”. 125 (3), s. 625–630, Jun 2012. DOI: 10.1016/j.ygyno.2012.03.015. PMID: 22426251.
A. Salar, C. Haioun, F.G. Rossi, U. Duehrsen i inni. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. „Leuk Res”. 36 (5), s. 548–553, May 2012. DOI: 10.1016/j.leukres.2012.02.002. PMID: 22385870.
K. Ozawa, H. Minami, H. Sato. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. „Cancer Chemother Pharmacol”. 62 (3), s. 551–557, Aug 2008. DOI: 10.1007/s00280-007-0648-8. PMID: 18064462.
W. Hosmer, J. Malin, M. Wong. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. „Support Care Cancer”. 19 (3), s. 333–341, Mar 2011. DOI: 10.1007/s00520-010-0821-1. PMID: 20179995.
J. Gea-Banacloche. Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies. „Hematology Am Soc Hematol Educ Program”. 2013, s. 414–422, 2013. DOI: 10.1182/asheducation-2013.1.414. PMID: 24319213.
N. Pherwani, J.M. Ghayad, L.M. Holle, E.L. Karpiuk. Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review. „Am J Health Syst Pharm”. 72 (8), s. 619–631, Apr 2015. DOI: 10.2146/ajhp140194. PMID: 25825185.
A. Uys, B.L. Rapoport, R. Anderson. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. „Support Care Cancer”. 12 (8), s. 555–560, Aug 2004. DOI: 10.1007/s00520-004-0614-5. PMID: 15197637.
L. de Souza Viana, J.C. Serufo, M.O. da Costa Rocha, R.N. Costa i inni. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients. „Support Care Cancer”. 16 (7), s. 841–846, Jul 2008. DOI: 10.1007/s00520-007-0347-3. PMID: 17960431.
E.P. Hui, L.K. Leung, T.C. Poon, F. Mo i inni. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. „Support Care Cancer”. 19 (10), s. 1625–1635, Oct 2011. DOI: 10.1007/s00520-010-0993-8. PMID: 20820815.
H. Innes, S.L. Lim, A. Hall, S.Y. Chan i inni. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. „Support Care Cancer”. 16 (5), s. 485–491, May 2008. DOI: 10.1007/s00520-007-0334-8. PMID: 17899215.
C. Fontanella, S. Bolzonello, B. Lederer, G. Aprile. Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. „Breast Care (Basel)”. 9 (4), s. 239–245, Apr 2014. DOI: 10.1159/000366466. PMID: 25404882.
L. Sung, D.L. Johnston. Approach to febrile neutropenia in the general paediatric setting. „Paediatr Child Health”. 12 (1), s. 19–21, Jan 2007. PMID: 19030334.
K.C. Lakshmaiah, A.S. Malabagi, R. Govindbabu, M. Shetty i inni. Febrile Neutropenia in Hematological Malignancies: Clinical and Microbiological Profile and Outcome in High Risk Patients. „J Lab Physicians”. 7 (2). s. 116–120. DOI: 10.4103/0974-2727.163126. PMID: 26417163.
P. Villafuerte-Gutierrez, L. Villalon, J.E. Losa, C. Henriquez-Camacho. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. „Adv Hematol”. 2014, s. 986938, 2014. DOI: 10.1155/2014/986938. PMID: 25525436.
M. Paul, D. Yahav, A. Bivas, A. Fraser i inni. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. „Cochrane Database Syst Rev”, s. CD005197, 2010. DOI: 10.1002/14651858.CD005197.pub3. PMID: 21069685.
M. Paul, Y. Dickstein, A. Schlesinger, S. Grozinsky-Glasberg i inni. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. „Cochrane Database Syst Rev”, s. CD003038, 2013. DOI: 10.1002/14651858.CD003038.pub2. PMID: 23813455.
A. Cometta, S. Zinner, R. de Bock, T. Calandra i inni. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. „Antimicrob Agents Chemother”. 39 (2), s. 445–452, Feb 1995. PMID: 7726513.
C. Cordonnier, R. Herbrecht, J.L. Pico, M. Gardembas i inni. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group. „Clin Infect Dis”. 24 (1), s. 41–51, Jan 1997. PMID: 8994754.
J.P. Flaherty, D. Waitley, B. Edlin, D. George i inni. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. „Am J Med”. 87 (5A), s. 278S-282S, Nov 1989. PMID: 2686429.
Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. „J Infect Dis”. 163 (5), s. 951–958, May 1991. PMID: 2019772.
O.A. Clark, G.H. Lyman, A.A. Castro, L.G. Clark i inni. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. „J Clin Oncol”. 23 (18), s. 4198–4214, Jun 2005. DOI: 10.1200/JCO.2005.05.645. PMID: 15961767.
R. García-Carbonero, J.I. Mayordomo, M.V. Tornamira, M. López-Brea i inni. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. „J Natl Cancer Inst”. 93 (1), s. 31–38, Jan 2001. PMID: 11136839.
L. Vidal, M. Paul, I. Ben dor, K. Soares-Weiser i inni. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. „J Antimicrob Chemother”. 54 (1), s. 29–37, Jul 2004. DOI: 10.1093/jac/dkh303. PMID: 15201227.
L. Vidal, I. Ben Dor, M. Paul, N. Eliakim-Raz i inni. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. „Cochrane Database Syst Rev”, s. CD003992, 2013. DOI: 10.1002/14651858.CD003992.pub3. PMID: 24105485.
O. Teuffel, M.C. Ethier, S.M. Alibhai, J. Beyene i inni. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. „Ann Oncol”. 22 (11), s. 2358–2365, Nov 2011. DOI: 10.1093/annonc/mdq745. PMID: 21363878.
S. Cetean, C. Căinap, A.M. Constantin, S. Căinap i inni. The importance of the granulocyte-colony stimulating factor in oncology. „Clujul Med”. 88 (4), s. 468–472, 2015. DOI: 10.15386/cjmed-531. PMID: 26732055.
C.L. Vogel, M.Z. Wojtukiewicz, R.R. Carroll, S.A. Tjulandin i inni. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. „J Clin Oncol”. 23 (6), s. 1178–1184, Feb 2005. DOI: 10.1200/JCO.2005.09.102. PMID: 15718314.
J.N. Timmer-Bonte, T.M. de Boo, H.J. Smit, B. Biesma i inni. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. „J Clin Oncol”. 23 (31), s. 7974–7984, Nov 2005. DOI: 10.1200/JCO.2004.00.7955. PMID: 16258098.
G.H. Lyman, D.C. Dale, E. Culakova, M.S. Poniewierski i inni. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. „Ann Oncol”. 24 (10), s. 2475–2484, Oct 2013. DOI: 10.1093/annonc/mdt226. PMID: 23788754.
L. Sung, P.C. Nathan, S.M. Alibhai, G.A. Tomlinson i inni. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. „Ann Intern Med”. 147 (6), s. 400–411, Sep 2007. PMID: 17876022.
P. Renner, S. Milazzo, J.P. Liu, M. Zwahlen i inni. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. „Cochrane Database Syst Rev”. 10, s. CD007913, 2012. DOI: 10.1002/14651858.CD007913.pub2. PMID: 23076939.
E.A. Engels, J. Lau, M. Barza. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. „J Clin Oncol”. 16 (3), s. 1179–1187, Mar 1998. PMID: 9508206.
A. Gafter-Gvili, A. Fraser, M. Paul, L. Leibovici. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. „Ann Intern Med”. 142 (12 Pt 1), s. 979–995, Jun 2005. PMID: 15968013.
E.J. Bow, E. Rayner, T.J. Louie. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. „Am J Med”. 84 (5), s. 847–854, May 1988. PMID: 3284340.
